STOCK TITAN

Pacira BioSciences (PCRX) Stock News, May-Jul 2026

PCRX NASDAQ

Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.

Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.

Rhea-AI Summary

Pacira BioSciences (NASDAQ:PCRX) released results from its national Standing Strong: The Impact of Pain on America's Workforce survey of 1,000 full-time U.S. workers whose jobs require time on their feet, conducted online from April 17 to May 3, 2026. The survey, which reflects only respondents’ experiences and opinions, found that 85% reported work-related orthopedic pain at least sometimes, and 41% often or all the time. More than half reported lost income due to pain, and 55% would choose a less physical career, rising to 73% among active military.

Knee pain was the most common complaint, with 56% reporting chronic knee pain. Among those with knee pain as their primary concern, 66% said it harms social life and relationships. Pacira highlighted strong interest in long-lasting, non-opioid options: among respondents with chronic knee pain, 24% used prescription opioids, yet 98% would consider a long-lasting, non-opioid treatment. The company underscored ZILRETTA, an extended-release intra-articular corticosteroid for osteoarthritis knee pain, alongside EXPAREL and iovera, and outlined key ZILRETTA safety information, including contraindications, serious and common side effects, and the fact that benefits and risks of repeat injections have not been demonstrated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (NASDAQ:PCRX) reported a successful transition of PCRX-201, its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based, scalable commercial manufacturing process designed to support future registrational development and commercialization. Availability of drug product from this process enabled enrollment of the first patient in Part B of the Phase 2 ASCEND study, while enrollment in Part A concluded in June with topline data expected by the end of 2026.

The two-part ASCEND trial will enroll about 135 patients, randomizing them 1:1:1 to two PCRX-201 dose levels or saline, all with corticosteroid pretreatment. The primary endpoint is safety over 52 weeks, with secondary pain and function outcomes through 52 weeks and five-year follow-up. According to Pacira, the process change did not delay ASCEND and further validates its high-capacity adenovirus (HCAd) platform, supporting PCRX-201’s progression alongside existing RMAT and ATMP designations and previously reported three-year durability and tolerability data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after U.S. market close on Tuesday, August 4, 2026. A live conference call and webcast will follow at 4:30 p.m. ET, with pre-registration required for telephone Q&A participation and a replay available on the company’s investor website for about two weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
earnings date
Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) granted inducement equity awards on July 2, 2026 to ten new employees under its 2014 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Four employees received stock options for 9,200 shares and ten employees received 18,200 restricted stock units, each with multi-year vesting tied to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (NASDAQ:PCRX) announced that UnitedHealthcare now provides separate reimbursement for EXPAREL across outpatient settings, including hospital outpatient departments and ambulatory surgery centers.

According to Pacira, this covers about 40 million UnitedHealthcare members and contributes to roughly 150 million covered lives with separate EXPAREL reimbursement nationwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) agreed to divest its iovera° cryoneurolysis pain-treatment business to Zimmer Biomet (NYSE:ZBH). Pacira will receive up to $140 million, including $70 million upfront and up to $70 million in revenue-based milestones through December 31, 2031.

The companies will also collaborate on a spasticity program, with potential extra compensation for Pacira, and Pacira plans to use upfront proceeds to pay down its senior secured revolving credit facility. Closing is expected in Q3 2026, subject to customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) announced that, based on preliminary results from its 2026 Annual Meeting of Stockholders, all three company director nominees — Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans — were elected to the board.

Final results will be certified and filed on Form 8-K with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
none
-
Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) urges stockholders to vote the BLUE proxy card for its three director nominees ahead of the June 9, 2026 annual meeting. Independent advisors ISS, Glass Lewis and Egan-Jones recommend supporting Pacira’s slate. Pacira highlights record 2025 revenue and margins, Q1 2026 EXPAREL, ZILRETTA and iovera° growth, and upcoming 2026 clinical readouts as reasons to maintain its current board and 5x30 strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.50%
Tags
none
Rhea-AI Summary

Pacira BioSciences (Nasdaq:PCRX) sent a letter urging stockholders to back its board nominees ahead of the June 9, 2026 annual meeting and support its 5x30 growth strategy.

Pacira highlights 2025 record revenue of $726.4M, GAAP net income of $7.0M, record gross margins, EXPAREL growth, new partnerships, and an EXPAREL patent settlement providing exclusivity into 2030 with a capped transition through 2039.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.50%
Tags
none

FAQ

What is the current stock price of Pacira BioSciences (PCRX)?

Pacira BioSciences (PCRX) last closed at $36.48.

What is the market cap of Pacira BioSciences (PCRX)?

The market cap of Pacira BioSciences (PCRX) is approximately $1.5B.